

REMARKS

Applicants believe that the present application is now in condition for allowance.
Favorable reconsideration of the application as amended is respectfully requested.

The Examiner is invited to contact the undersigned by telephone if it is felt that a telephone interview would advance the prosecution of the present application.

Respectfully submitted,

Date April 28, 2003

Frommer Lawrence & Haug, LLP
745 Fifth Avenue
New York NY USA 10151
Telephone: 212-588-0800
Facsimile: 212-588-0500

By Amy Leahy

Amy Leahy
Registration No. 47,739

Should additional fees be necessary in connection with the filing of this paper, or if a petition for extension of time is required for timely acceptance of same, the Commissioner is hereby authorized to charge Deposit Account No. 50-0320 for any such fees; and applicants hereby petition for any needed extension of time.

MARKED UP VERSION ATTACHED TO AMENDMENT IN

SERIAL NO. 09/872,832

Marked up version of the paragraph starting at page 14, lines 16-18 is below:

The HLA can be A1 and the T cell specific epitope can be YTSDYFISY (SEQ ID NO: 1), YLDDPDLKY (SEQ ID NO: 2), IADMGHLKY (SEQ ID NO: 3), STDHIPILY (SEQ ID NO: 4), DSDGSFFLY (SEQ ID NO: 5), ATDFKFAMY (SEQ ID NO: 6), YTAVVPLVY (SEQ ID NO: 7) and YTDYGGGLIFNSY (SEQ ID NO: 8).

Marked up version of the paragraph starting at page 14, lines 19-21 is below:

The HLA can be A2.1 and the T cell specific epitope can be LLDVPTAAV (SEQ ID NO: 9), SLLPAIVEL (SEQ ID NO: 10), YLLPAIVEI (SEQ ID NO: 11), MVDGTLLLL (SEQ ID NO: 12), YMNGTMSQV (SEQ ID NO: 13), MLLSVPLLLG (SEQ ID NO: 14), LLLDVPTAAV (SEQ ID NO: 15), LLLDVPTAAVQA (SEQ ID NO: 16), and VLFRGGPRGLLAVA (SEQ ID NO: 17).

Marked up version of the paragraph starting at page 14, lines 22-23 is below:

The HLA can be A11 and the T cell specific epitope can be SVLNLVIVK (SEQ ID NO: 18), KVVNPLFEK (SEQ ID NO: 19), RTQNVLGEK (SEQ ID NO: 20), ASFDKAKLK (SEQ ID NO: 21), and ATAGDGXXELRK (SEQ ID NO: 22).

Marked up version of the paragraph starting at page 14, lines 24-25 is below:

The HLA can be A24 and the T cell specific epitope can be KYPNEFFLL (SEQ ID NO: 23), YYEEQHPEL (SEQ ID NO: 24), AYVHMTVTHF (SEQ ID NO: 25), and VYXKHPVSX (SEQ ID NO: 26).

Marked up version of the paragraph starting at page 14, lines 26-27 is below:

The HLA can be A68.1 and the T cell specific epitope can be DVFRDPALK (SEQ ID NO: 27), KTGGPYIKR (SEQ ID NO: 28), and TVFDAKRLIGR (SEQ ID NO: 29).

Marked up version of the paragraph starting at page 15, lines 1-3 is below:

The HLA can be B7 and the T cell specific epitope can be APRTVALTA (SEQ ID NO: 30), APRTLVLALL (SEQ ID NO: 31), APRPPPKPM (SEQ ID NO: 32), SPRYIFTML (SEQ ID NO: 33), RPKSNIVLL (SEQ ID NO: 34), LVMAPRTVL (SEQ ID NO: 35), APRTVALTAL (SEQ ID NO: 36), and AASKERSGVSL (SEQ ID NO: 37).

Marked up version of the paragraph starting at page 15, lines 4-5 is below:

The HLA can be B27 and the T cell specific epitope can be RRIKEIVKK (SEQ ID NO: 38), GRIDKPILK (SEQ ID NO: 39), RRSKEITVR (SEQ ID NO: 40), RRVKEVVKK (SEQ ID NO: 41), and RRYQKSTWL (SEQ ID NO: 42).

Marked up version of the paragraph starting at page 39, lines 16-21 is below:

The EBV-encoded latent membrane protein 1 (LMP1) is consistently expressed in EBV-associated malignancies, and the peptide epitope YLLEMLWRL (SEQ ID NO: 48) derived from LMP1 (LMP1.1) is presented in the context of the HLA class I molecule A2.1. Starting from peripheral blood T cells harvested from HLA A2.1⁺ donors, it was shown that the AAPCs consistently elicit strong stimulation of CTLs with HLA-restricted specific cytotoxic activity against the LMP1.1 peptide.

Marked up version of Claim 26 is below:

26. (amended) The AAPC according to claim 3, wherein the HLA is A1 and the T cell specific epitope is selected from the group consisting of YTSDYFISY (SEQ ID NO: 1), YLDDPDLKY

(SEQ ID NO: 2), IADMGHLKY (SEQ ID NO: 3), STDHIPILY (SEQ ID NO: 4), DSDGSFFLY (SEQ ID NO: 5), ATDFKFAMY (SEQ ID NO: 6), YTAVVPLVY (SEQ ID NO: 7) and YTDYGGLIFNSY (SEQ ID NO: 8).

Marked up version of Claim 27 is below:

27. (amended) The AAPC according to claim 3, wherein the HLA is A2.1 and the T cell specific epitope is selected from the group consisting of LLDVPTAAV (SEQ ID NO: 9), SLLPAIVEL (SEQ ID NO: 10), YLLPAIVEI (SEQ ID NO: 11), MVDGTLILL (SEQ ID NO: 12), YMNGTMSQV (SEQ ID NO: 13), MLLSVPLLLG (SEQ ID NO: 14), LLDVPTAAV (SEQ ID NO: 15), LLDVPTAAVQA (SEQ ID NO: 16), and VLFRGGPRGLLAVA (SEQ ID NO: 17).

Marked up version of Claim 28 is below:

28. (amended) The AAPC according to claim 3, wherein the HLA is A11 and the T cell specific epitope is selected from the group consisting of SVLNLVIVK (SEQ ID NO: 18), KVVNPLFEK (SEQ ID NO: 19), RTQNVLGEK (SEQ ID NO: 20), ASFDKAKLK (SEQ ID NO: 21), and ATAGDGXXELRK (SEQ ID NO: 22).

Marked up version of Claim 29 is below:

29. (amended) The AAPC according to claim 3, wherein the HLA is A24 and the T cell specific epitope is selected from the group consisting of KYPNEFFLL (SEQ ID NO: 23), YYEEQHPEL (SEQ ID NO: 24), AYVHVMVTHF (SEQ ID NO: 25), and VYXKHPVSX (SEQ ID NO: 26).

Marked up version of Claim 30 is below:

30. (amended) The AAPC according to claim 3, wherein the HLA is A68.1 and the T cell specific epitope is selected from the group consisting of DVFRDPALK (SEQ ID NO: 27), KTGGPIYKR (SEQ ID NO: 28), and TVFDAKRLIGR (SEQ ID NO: 29).

Marked up version of Claim 31 is below:

31. **(amended)** The AAPC according to claim 3, wherein the HLA is B7 and the T cell specific epitope is selected from the group consisting of APRTVALTA **(SEQ ID NO: 30)**, APRTLVLALL **(SEQ ID NO: 31)**, APRPPKPM **(SEQ ID NO: 32)**, SPRYIFTML **(SEQ ID NO: 33)**, RPKSNIVLL **(SEQ ID NO: 34)**, LVMAPRTVL **(SEQ ID NO: 35)**, APRTVALTAL **(SEQ ID NO: 36)**, and AASKERSGVSL **(SEQ ID NO: 37)**.

Marked up version of Claim 32 is below:

32. **(amended)** The AAPC according to claim 3, wherein the HLA is B27 and the T cell specific epitope is selected from the group consisting of RRIKEIVKK **(SEQ ID NO: 38)**, GRIDKPILK **(SEQ ID NO: 39)**, RRSKEITVR **(SEQ ID NO: 40)**, RRVKEVVKK **(SEQ ID NO: 41)**, and RRYQKSTWL **(SEQ ID NO: 42)**.